Cerebral Amyloid Angiopathy: Vascular Imaging and fluid markers of Amyloid depositio

Completed

• Conditions: neurodegenerative aandoeningen (vasculair); Cerebral amyloid angiopathy; small vessel disease; 10007963

• Registration Number: NL-OMON42188
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

Inclusion criteria for sporadic CAA group:
- Fulfilment of the modified Boston criteria for Cerebral Amyloid Angiopathy (CAA);Inclusion criteria for late-onset AD group:
- Fulfillment of the diagnostic criteria
- Available T2* MRI scan with information on presence or absence of CAA;Inclusion criteria for RUNDMC participants:
- Participants in the ongoing RUNDMC study (PI dr. FE de Leeuw) will be selected for the likelihood of the presence or absence of CAA, based on T2* MRI investigations that are already available.

Exclusion Criteria

Exclusion criteria for MRI:
- Metal parts in the body (pacemaker, neurostimulator, clips, medication pumps, port-a-cath, hearing aids, cochlear implants, prostheses, piercings)
- Claustrofobia
- Difficulty with lying down for more than 30 minutes
- Pregnancy ;Exclusion criteria for Lumbar puncture:
- Allergy to local anesthetic agents
- Medical history of compression of spinal cord, spinal surgery, skin infection, developmental abnormalities in lower spine, blood coagulopathy, anticoagulant medication.
- Clinical (or previous MRI) evidence of structural (space occupying) cerebral abnormalities that are not compatible with the performance of an LP including malignancies, abscess or obstructive hydrocephalus.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>• develop and validate sensitive and specific body fluid and neuroimaging<br /><br>biomarkers to detect CAA during life. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>• correlate novel neurochemical and neuroimaging biomarkers with each other and<br /><br>with measures of cognitive decline </p><br>